Dr. John Shiver is a recognized expert and industry leader in vaccine and pharmaceutical research and development. He has guided numerous scientific teams that created novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including HIV, influenza, HPV, RSV, CMV, pneumococcus, meningococcus, gonorrhea, cancer, and asthma. He has collaborated with other senior leaders to secure the licensure of pharmaceutical products spanning both vaccines and monoclonal antibodies, many of which were first- and/or best-in-class products addressing global infectious diseases.

Dr. Shiver was the SVP and Global Head of Vaccines R&D and a member of the Executive Leadership team for 8 years at Sanofi Pasteur and previously spent 22 years at Merck & CO where he held a series of senior leadership positions with his last position being VP and Head of Vaccines and Biologics Research. He was a member of Merck Vaccines Integrated Leadership Team and the Global Research Leadership Committee responsible for vaccine research, vaccine clinical assays and biomarkers, and biologics research, and siRNA technologies.

Dr. Shiver is a Fellow of the American Academy of Microbiology and the International Society of Vaccines (ISV) and a member of multiple advisory boards, including the Board of Directors for the nonprofit International AIDS Vaccine Initiative (IAVI), and Boards of Directors for NovaVax, Icosavax (acquired by AstraZeneca in 2024), Auravax, and Calder BioSciences.  He has also served on the Executive Board of the International Society for Vaccines and on several journal editorial boards, including Nature Partner Journals Vaccines and the Journal of Virology. He is the author of more than 150 articles and is a co-author of over 70 awarded patents. Dr. Shiver holds a Ph.D. in Physical Chemistry from the University of Florida in Gainesville, FL and a Bachelor of Science degree in Chemistry from Wofford College in Spartanburg, SC.